BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 19, 2008
View Archived Issues
Possible Vasculitis Case Halts Heplisav Trials, Dynavax Falls
The news sent shares of Dynavax (NASDAQ:DVAX) plunging 58.6 percent, closing Tuesday at $2.16, down $3.06. (BioWorld Today)
Read More
Nuvelo Halting Alfimeprase After Phase II Study Failure
Read More
Approval Letter on Ceftobiprole Sends Basilea Shares Plunging
Read More
Alimera Closes $30M Financing, Boosts Stake in Medidur FA
Read More
BioNumerik's Tavocept Shows Trend Only in 'Small' Phase III
Read More
Prometic, Sartorius Pact Taps into Asian Markets
Read More
Other News To Note
Read More
Clinic Roundup
Read More